Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RORC | P51449 | 12/20 | 0.44 |
| ▸ | MGLL | Q99685 | 2/20 | 0.42 |
| ▸ | JAK1 | P23458 | 1/20 | 0.38 |
| ▸ | KDM1A | O60341 | 1/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.36 |
| ▸ | GPR119 | Q8TDV5 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4629807 | 1.00 | RORC (0.44) | RORCMGLLJAK1KDM1AKDM4E | |
| SCHEMBL8247516 | 1.00 | RORC (0.44) | RORCMGLLJAK1KDM1AKDM4E | |
| SCHEMBL4629158 | 1.00 | RORC (0.44) | RORCMGLLJAK1KDM1AKDM4E | |
| SCHEMBL2714917 | 0.88 | RORC (0.44) | RORCMGLLJAK1KDM1A | |
| SCHEMBL12313218 | 0.88 | RORC (0.57) | RORCMGLL | |
| SCHEMBL23752795 | 0.88 | MGLL (0.54) | RORCMGLL | |
| SCHEMBL5242538 | 0.88 | RORC (0.57) | RORCMGLL | |
| SCHEMBL2712886 | 0.88 | RORC (0.57) | RORCMGLL | |
| SCHEMBL9951030 | 0.88 | RORC (0.57) | RORCMGLL | |
| SCHEMBL2975631 | 0.88 | RORC (0.44) | RORCMGLLJAK1KDM1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7776904-B2 | Azabicyclo [3.1.0] hexylphenyl derivatives as modulators of dopamine D3 receptors | GLAXO GROUP LIMITED (GB) | 2010-08-17 | — | — | US | disclosed |
| US-20090030062-A1 | AZABICYCLO [3.1.0] HEXYLPHENYL DERIVATIVES AS MODULATORS OF DOPAMINE D3 RECEPTORS | GLAXO GROUP LIMITED | 2009-01-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090030062-A1 | AZABICYCLO [3.1.0] HEXYLPHENYL DERIVATIVES AS MODULATORS OF DOPAMINE D3 RECEPTORS | DRD3, DRD2, HTR3C | RORC 673/4885MGLL 4516/4885JAK1 1667/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.